William Pridgen - 23 Mar 2022 Form 4 Insider Report for Virios Therapeutics, Inc. (DWTX)

Role
Director
Signature
/s/ Greg Duncan, Attorney-in-Fact
Issuer symbol
DWTX
Transactions as of
23 Mar 2022
Net transactions value
+$12,002
Form type
4
Filing time
24 Mar 2022, 14:52:33 UTC
Previous filing
28 Jan 2022
Next filing
30 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRI Common Stock Purchase $12,002 +2,197 +11% $5.46* 22,419 23 Mar 2022 401 (k) Account F1, F2, F3
holding VIRI Common Stock 709,234 23 Mar 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.37 to $5.48, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2 Reflects corrected holdings, as prior reports incorrectly understated indirect holdings and overstated direct holdings, by 1,500 shares.
F3 The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee.